Preparing for the ICH E6 (R2) Addendum: A 3-Part Series
June 13th 2016This 3-part series provides insight into ensuring compliance with the ICH E6 (R2) Addendum to take effect later this year. Part 2 covers steps that organizations can take today to begin adopting a centralized technology-based approach to risk management.
Avoid Shortcuts on Route to Data Anonymization
June 3rd 2016Faced with new EMA guidance on anonymizing clinical trial data, drug manufacturers have two choices – do what it takes to meet the November deadline and prioritize clinical study reports, or embrace a more sustainable strategy that starts with the patient-level data.
A New Approach to an Old Problem – Speeding Study Startup
June 2nd 2016While launching a new clinical study is an exciting stage of product development for trial personnel, road blocks can emerge. A new approach is needed to cope with the volume of activates required for the study product registration.